Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol loxenatide (Hansoh Pharmaceutical Group)
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Polyethylene glycol loxenatide (PEX168) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes mellitus. It is a modified version of exenatide, where the addition of a polyethylene glycol (PEG) moiety extends its half-life and duration of action, allowing for once-weekly subcutaneous administration. By activating the GLP-1 receptor, it enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying, thereby improving glycemic control and potentially aiding in weight reduction. It was developed by Hansoh Pharmaceutical and is approved in China for the treatment of type 2 diabetes. Nanjing First Hospital, Nanjing Medical University has been involved in conducting Phase 4 clinical studies to further evaluate its efficacy on metabolic factors and body composition.
- Brand names
- Fulaimei
- Other names
- polyethylene glycol losenatidePEG-loxenatidePEG-losenatide
02
Targets
Beyond the preview
Go deeper on polyethylene glycol loxenatide (Hansoh Pharmaceutical Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol loxenatide (Hansoh Pharmaceutical Group).